Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

Clinical trial NCT04360096 · TERMINATED

Trial details

NCT number: NCT04360096
Sponsor: APR Applied Pharma Research s.a.
Status: TERMINATED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

SARS-CoV 2 COVID ARDS ALI Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Dyspnea

Start date: 2021-02-15
Primary completion: 2021-12-15
Enrollment: 144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.